FFAR1; FFAR4; ADRA2C; ADRA2A; GPBAR1; HCAR2; | |
TSHR; NMUR2; | |
ALPI; PLA2G1B; TDP1; BLM; FAAH; RECQL; CTDSP1; TERT; PKM; HPGD; HSD17B1; AKR1B1; HSD17B10; IDO1; ALOX15; ALDH1A1; HSD17B2; AKR1B10; NOX4; BRCA1; APEX1; POLB; | |
PTPN1; CDC25B; PTPN2; | |
ACHE; GAA; | |
TRPA1; | |
CDK8; DAPK1; FLT3; CDK9; MAPK1; | |
CA3; CA14; CA5B; CA6; CA1; CA9; CA7; CA4; CA2; CA12; CA5A; | |
AR; | |
NR1H4; | |
ESRRA; | |
PPARA; PPARG; PPARD; | |
KDM4E; | |
ALOX5; PTGS1; TYR; XDH; | |
CASP7; CASP1; | |
MMP1; | |
TLR2; | |
AHR; HIF1A; TP53; | |
ABCC1; ABCG2; | |
LMNA; FABP5; FABP2; FABP4; MCL1; MAPT; FABP3; RAB9A; NPC1; TTR; | |
L3MBTL1; SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.415E-10 | 2.144E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.738E-10 | 2.231E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.790E-09 | 6.388E-07 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 7.497E-09 | 2.163E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.196E-07 | 2.578E-05 | APEX1, AR, BLM, BRCA1, CASP7, CYP1A1, CYP1B1, FLT3, MAPK1, NOX4, NPC1, PPARG |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 3.572E-07 | 7.007E-05 | ABCC1, ALOX15, ALOX5, PLA2G1B, TLR2 |
BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 5.112E-07 | 9.355E-05 | AHR, AKR1B1, APEX1, CA3, CYP1A1, CYP1B1, HPGD, MAPK1, POLB, TLR2, TP53, TRPA1 |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 1.043E-06 | 1.774E-04 | AR, CDK8, CDK9, ESRRA, NR1H4, PPARA, PPARD, PPARG |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.370E-06 | 2.211E-04 | CYP19A1, FFAR4, NR1H4, PPARA, PPARD, PPARG, PTPN2 |
BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 2.045E-06 | 3.009E-04 | AHR, AR, BRCA1, ESRRA, NR1H4, PPARA, PPARD, PPARG |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 3.608E-04 | 3.049E-03 | AKR1B10; GAA; AKR1B1 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 9.264E-09 | 3.131E-07 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 9.668E-07 | 1.634E-05 | CYP2A6; CYP1A2; XDH |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 3.522E-05 | 3.968E-04 | CYP1A2; CYP1A1; CYP1B1; IDO1 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 4.280E-07 | 9.042E-06 | CYP2C9; PLA2G1B; ALOX5; ALOX15; CYP2C19; PTGS1 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.741E-09 | 2.107E-07 | CYP2C9; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 5.687E-07 | 1.068E-05 | CYP2C9; CYP2A6; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.442E-22 | 2.436E-20 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.138E-06 | 1.748E-05 | CYP2C9; CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.733E-05 | 2.092E-04 | CYP2C9; CYP2A6; CYP1A2; CYP3A4; CYP2C19 |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | TLR2; PKM; FLT3; CA9; HIF1A; MAPK1; TP53 |